title: Suppression of the Hypothalamic-pituitary-adrenal Axis by Maximum Androgen Blockade in a Patient with Prostate Cancer.
abstract: A 78-year-old Japanese man showed suppression of the hypothalamic-pituitary-adrenal axis during maximum androgen blockade (MAB) therapy including chlormadinone acetate (CMA) for prostate cancer. After stopping the MAB therapy, both the basal ACTH level and the response to CRH recovered. While no reports have indicated that CMA suppresses the hypothalamic-pituitary-adrenal axis in patients with prostate cancer, CMA has been shown to inhibit this axis in animals. These observations suggest that we must monitor the hypothalamic-pituitary-adrenal axis in patients treated with CMA, especially under stressful conditions.
authors.affiliation: Department of Hematology, Endocrinology & Metabolism Institute of Biomedical Sciences, Tokushima University Graduate School, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kondo
authors.forename: Itsuro
authors.initials: I
authors.lastname: Endo
authors.forename: Yukari
authors.initials: Y
authors.lastname: Ooguro
authors.forename: Kana
authors.initials: K
authors.lastname: Morimoto
authors.forename: Kiyoe
authors.initials: K
authors.lastname: Kurahashi
authors.forename: Sumiko
authors.initials: S
authors.lastname: Yoshida
authors.forename: Akio
authors.initials: A
authors.lastname: Kuroda
authors.forename: Ken-Ichi
authors.initials: KI
authors.lastname: Aihara
authors.forename: Munehide
authors.initials: M
authors.lastname: Matsuhisa
authors.forename: Masahiro
authors.initials: M
authors.lastname: Abe
authors.forename: Seiji
authors.initials: S
authors.lastname: Fukumoto
mesh_terms: D000311:Adrenal Glands / Q000187:drug effects; D000324:Adrenocorticotropic Hormone / Q000097:blood; D000368:Aged; D000726:Androgen Antagonists / Q000008:administration & dosage*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002715:Chlormadinone Acetate / Q000627:therapeutic use; D003346:Corticotropin-Releasing Hormone / Q000494:pharmacology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects* / Q000473:pathology; D008297:Male; D010913:Pituitary-Adrenal System / Q000187:drug effects* / Q000473:pathology; D011471:Prostatic Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D002715:Chlormadinone Acetate; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone